within Pharmacolibrary.Drugs.D_Dermatologicals.D01B_AntifungalsForSystemicUse.D01BA01_Griseofulvin;

model Griseofulvin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.3,
    Cl = 8.750000000000001e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0007,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004666666666666667,
    Tlag = 900);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Griseofulvin</td></tr><tr><td>ATC code:</td><td>D01BA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.45</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Griseofulvin is an antifungal medication primarily used to treat dermatophytic infections (skin, hair, nails) caused by Trichophyton, Microsporum, and Epidermophyton species. It inhibits fungal cell mitosis by interfering with microtubule function. Griseofulvin is approved and used in human medicine, although its use has declined due to newer antifungal agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration of griseofulvin micronized tablets.</p><h4>References</h4><ol><li><p>Gupta, AK, et al., &amp; Cooper, EA (2003). The efficacy and safety of terbinafine in children. <i>Journal of the European Academy of Dermatology and Venereology : JEADV</i> 17(6) 627–640. DOI:<a href=\"https://doi.org/10.1046/j.1468-3083.2003.00691.x\">10.1046/j.1468-3083.2003.00691.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14761128/\">https://pubmed.ncbi.nlm.nih.gov/14761128</a></p></li><li><p>Silva, MI, et al., &amp; Halbert, GW (2023). Fed intestinal solubility limits and distributions applied to the Developability classification system. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 186 74–84. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2023.03.005\">10.1016/j.ejpb.2023.03.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36934829/\">https://pubmed.ncbi.nlm.nih.gov/36934829</a></p></li><li><p>Gupta, AK, et al., &amp; Tavakkol, A (2005). The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. <i>Journal of drugs in dermatology : JDD</i> 4(3) 302–308. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15898285/\">https://pubmed.ncbi.nlm.nih.gov/15898285</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D01BA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Griseofulvin;
